Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Marinus Pharmaceuticals, Inc. - Common Stock (NQ:MRNS)

0.5500 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Marinus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
Earnings Scheduled For August 10, 2021 ↗
Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter. • Fulcrum Therapeutics (NASDAQ:... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
News headline image
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
Marinus' Oral Ganaxolone Lowers Seizure Frequency In Genetic Disorder ↗
Marinus Pharmaceuticals Inc (NASDAQ: MRNS) announced topline data from its open-label Phase 2 trial evaluating oral ganaxolone in patients with seizures associated with... 
Via Benzinga
News headline image
Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals: Q2 Earnings Insights ↗
Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share fell 306.25% over the past year... 
Via Benzinga
News headline image
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Files US Application For Ganaxolone For Genetic Epilepsy, Inks European Commercialization Pact With Orion ↗
Marinus Pharmaceuticals Inc (NASDAQ: MRNS) has submitted a marketing application to the FDA seeking approval for its lead product candidate, ganaxolone, to treat... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
News headline image
Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline Update
From Marinus Pharmaceuticals
Via Business Wire
News headline image
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
News headline image
Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Santiago Arroyo, M.D., Ph.D.
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Marinus Pharmaceuticals, Inc.
Via Business Wire
News headline image
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals: Q1 Earnings Insights ↗
Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share decreased 131.25% over the past... 
Via Benzinga
News headline image
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Reschedules First Quarter 2021 Financial Results Conference Call
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Earnings Scheduled For May 17, 2021 ↗
Companies Reporting Before The Bell • Hycroft Mining Holding (NASDAQ:HYMC) is estimated to report earnings for its first quarter. • U.S. Well Services (NASDAQ:... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Alexion Pharmaceuticals, Inc... 
Via Benzinga
News headline image
Earnings Scheduled For May 13, 2021 ↗
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million. •... 
Via Benzinga
News headline image
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings ↗
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
News headline image
Marinus Pharmaceuticals to Provide Business Update and Announce First Quarter 2021 Financial Results on May 13, 2021
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Bolsters Leadership Team with Two New Appointments
From Marinus Pharmaceuticals
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.